Literature DB >> 1185015

Experimental osteomyelitis. IV. Therapeutic trials with rifampin alone and in combination with gentamicin, sisomicin, and cephalothin.

C W Norden.   

Abstract

Levels of rifampin, gentamicin, sisomicin, and cephalothin in normal and osteomyelitic rabbit bones were measured, and the efficacy of these drugs in the treatment of osteomyelitis was evaluated. Single drug regimens, including rifampin for 14 days and gentamicin, sisomicin, and cephalothin each for 28 days, were relatively ineffective (5%-33% sterile bone cultures). Rifampin, administered for 28 days, sterilized the bones of 55% of treated animals. The combination of gentamicin and rifampin, given for either 14 or 28 days, sterilized the bones of 67% of treated animals. The combinations of rifampin plus sisomicin and of rifampin plus cephalothin, given for 28 days, were significantly more effective than these agents alone, sterilizing 90%-95% of bones. The combination of rifampin, sisomicin, and cephalothin, given for only 14 days, sterilized the bones of all treated rabbits. Staphylococci isolated from the bones of therapeutic failures that had received rifampin alone or in combination with other antibiotics were highly resistant to rifampin (minimal inhibitory concentration, greater than 250 mug/ml), whereas the organisms recovered from animals not receiving rifampin remained sensitive. Results of in vitro studies of synergy and/or bactericidal activity of antibiotic combinations correlated with in vivo results in some, but not all, instances.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1185015     DOI: 10.1093/infdis/132.5.493

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  17 in total

Review 1.  In vivo antibiotic synergism: contribution of animal models.

Authors:  B Fantin; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

2.  Antimicrobial therapy for bone and joint infections.

Authors:  Saima Aslam; Rabih O Darouiche
Journal:  Curr Infect Dis Rep       Date:  2009-01       Impact factor: 3.725

3.  Intraocular penetration of rifampin after oral administration.

Authors:  K W Wong; D J D'Amico; B S Oum; P A Baker; K R Kenyon
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1990       Impact factor: 3.117

Review 4.  Significance of tissue levels for prediction of antibiotic efficacy and determination of dosage.

Authors:  C Carbon
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-07       Impact factor: 3.267

5.  In vivo verification of in vitro model of antibiotic treatment of device-related infection.

Authors:  J Blaser; P Vergères; A F Widmer; W Zimmerli
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191

6.  In vitro activity of rifampin in combination with oxacillin against Staphylococcus aureus.

Authors:  M Maduri Traczewski; D A Goldmann; P Murphy
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

Review 7.  Scope and limitations of experimental chemotherapy.

Authors:  O Zak
Journal:  Experientia       Date:  1980-04-15

Review 8.  Cefepime clinical pharmacokinetics.

Authors:  M P Okamoto; R K Nakahiro; A Chin; A Bedikian
Journal:  Clin Pharmacokinet       Date:  1993-08       Impact factor: 6.447

9.  Local penetration of gentamicin into the femoral cortex of rats.

Authors:  Y Mirovsky; N Halperin; L Copeliovitch
Journal:  Arch Orthop Trauma Surg       Date:  1984

10.  Comparative evaluation of A-56619, A-56620, and nafcillin in the treatment of experimental Staphylococcus aureus osteomyelitis.

Authors:  J T Mader; L T Morrison; K R Adams
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.